A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF ANTIANGINAL DRUGS OF DIFFERENT GROUPS — NITROVASODILATATOR (ISOSORBIDE-5-MONONITRATE SUSTAINED RELEASE) AND BETA-BLOCKER WITH VASODILATING ACTION (NEBIVOLOL) — IN PATIENTS WITH STABLE ANGINA

Aim. To compare the efficacy and safety of the slow-release isosorbide-5-mononitrate and of the nebivolol in patients with stable angina. Material and Methods. Patients (n=19) with ischemic heart disease (stable angina) were enrolled into randomized, double-blind, placebo-controlled, crossover study...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Yu. Martsevich, N. P. Kutishenko, V. A. Egorov, A. V. Zagrebel'nyy, A. A. Serazhim, Yu. V. Lukina, N. A. Dmitrieva
Format: Article
Language:English
Published: Столичная издательская компания 2016-01-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/897
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849227817572630528
author S. Yu. Martsevich
N. P. Kutishenko
V. A. Egorov
A. V. Zagrebel'nyy
A. A. Serazhim
Yu. V. Lukina
N. A. Dmitrieva
author_facet S. Yu. Martsevich
N. P. Kutishenko
V. A. Egorov
A. V. Zagrebel'nyy
A. A. Serazhim
Yu. V. Lukina
N. A. Dmitrieva
author_sort S. Yu. Martsevich
collection DOAJ
description Aim. To compare the efficacy and safety of the slow-release isosorbide-5-mononitrate and of the nebivolol in patients with stable angina. Material and Methods. Patients (n=19) with ischemic heart disease (stable angina) were enrolled into randomized, double-blind, placebo-controlled, crossover study. They alternatively received nebivolol 5 mg QD or slow-release isosorbide-5-mononitrate 50 mg QD. The drug efficacy was assessed by changes in symptoms, angina attack number , sublingual nitroglycerin need, and treadmill test duration. Results. Patients treated with isosorbide-5-mononitrate shown significant increase in heart rate (HR) at rest in all time check-points in comparison with patients receiving placebo. HR significantly decreased 2 hours after nebivolol intake both single one and after 30 days of treatment (p<0.001). Duration of treadmill exercise significantly increased (vs placebo) 2 hours after a single intake of both isosorbide-5-mononitrate (454.3±37.1 vs 310.6±13.3 s; p <0.001) and nebivolol (428.6±33.3 vs 310.6±13.3 s; p<0.01). In one month of treatment isosorbide- 5-mononitrate and nebivolol reduced a number of angina episodes vs placebo (5.6±2.1 and 4.3±1.4, respectively , vs 8.6±2.4 episodes per month; p<0.05), the need for nitroglycerin (5.5±2.6 and 3.1±1.2, respectively , vs 6.7±2.2 sublingual tablets/month; p>0.05). No significant differences of these indicators were found between studied drugs. Conclusion. Nebivolol 5 mg daily is not inferior to slow-release isosorbide-5-mononitrate 50 mg daily in antianginal efficacy , significantly reduces HR, and much less causes headache and other side effects.
format Article
id doaj-art-bc20dcd4a80b43dc8ca73ac98d2de35e
institution Kabale University
issn 1819-6446
2225-3653
language English
publishDate 2016-01-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj-art-bc20dcd4a80b43dc8ca73ac98d2de35e2025-08-23T10:00:23ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-017555556010.20996/1819-6446-2011-7-5-41-45896A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF ANTIANGINAL DRUGS OF DIFFERENT GROUPS — NITROVASODILATATOR (ISOSORBIDE-5-MONONITRATE SUSTAINED RELEASE) AND BETA-BLOCKER WITH VASODILATING ACTION (NEBIVOLOL) — IN PATIENTS WITH STABLE ANGINAS. Yu. Martsevich0N. P. Kutishenko1V. A. Egorov2A. V. Zagrebel'nyy3A. A. Serazhim4Yu. V. Lukina5N. A. Dmitrieva6State Research Center for Preventive MedicineState Research Center for Preventive MedicineState Research Center for Preventive MedicineState Research Center for Preventive MedicineCity polyclinic №93State Research Center for Preventive MedicineState Research Center for Preventive MedicineAim. To compare the efficacy and safety of the slow-release isosorbide-5-mononitrate and of the nebivolol in patients with stable angina. Material and Methods. Patients (n=19) with ischemic heart disease (stable angina) were enrolled into randomized, double-blind, placebo-controlled, crossover study. They alternatively received nebivolol 5 mg QD or slow-release isosorbide-5-mononitrate 50 mg QD. The drug efficacy was assessed by changes in symptoms, angina attack number , sublingual nitroglycerin need, and treadmill test duration. Results. Patients treated with isosorbide-5-mononitrate shown significant increase in heart rate (HR) at rest in all time check-points in comparison with patients receiving placebo. HR significantly decreased 2 hours after nebivolol intake both single one and after 30 days of treatment (p<0.001). Duration of treadmill exercise significantly increased (vs placebo) 2 hours after a single intake of both isosorbide-5-mononitrate (454.3±37.1 vs 310.6±13.3 s; p <0.001) and nebivolol (428.6±33.3 vs 310.6±13.3 s; p<0.01). In one month of treatment isosorbide- 5-mononitrate and nebivolol reduced a number of angina episodes vs placebo (5.6±2.1 and 4.3±1.4, respectively , vs 8.6±2.4 episodes per month; p<0.05), the need for nitroglycerin (5.5±2.6 and 3.1±1.2, respectively , vs 6.7±2.2 sublingual tablets/month; p>0.05). No significant differences of these indicators were found between studied drugs. Conclusion. Nebivolol 5 mg daily is not inferior to slow-release isosorbide-5-mononitrate 50 mg daily in antianginal efficacy , significantly reduces HR, and much less causes headache and other side effects.https://www.rpcardio.online/jour/article/view/897beta-blockerisosorbide-5-mononitrateantianginal efficacyischemic heart diseaseexercise tolerance testside effects
spellingShingle S. Yu. Martsevich
N. P. Kutishenko
V. A. Egorov
A. V. Zagrebel'nyy
A. A. Serazhim
Yu. V. Lukina
N. A. Dmitrieva
A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF ANTIANGINAL DRUGS OF DIFFERENT GROUPS — NITROVASODILATATOR (ISOSORBIDE-5-MONONITRATE SUSTAINED RELEASE) AND BETA-BLOCKER WITH VASODILATING ACTION (NEBIVOLOL) — IN PATIENTS WITH STABLE ANGINA
Рациональная фармакотерапия в кардиологии
beta-blocker
isosorbide-5-mononitrate
antianginal efficacy
ischemic heart disease
exercise tolerance test
side effects
title A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF ANTIANGINAL DRUGS OF DIFFERENT GROUPS — NITROVASODILATATOR (ISOSORBIDE-5-MONONITRATE SUSTAINED RELEASE) AND BETA-BLOCKER WITH VASODILATING ACTION (NEBIVOLOL) — IN PATIENTS WITH STABLE ANGINA
title_full A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF ANTIANGINAL DRUGS OF DIFFERENT GROUPS — NITROVASODILATATOR (ISOSORBIDE-5-MONONITRATE SUSTAINED RELEASE) AND BETA-BLOCKER WITH VASODILATING ACTION (NEBIVOLOL) — IN PATIENTS WITH STABLE ANGINA
title_fullStr A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF ANTIANGINAL DRUGS OF DIFFERENT GROUPS — NITROVASODILATATOR (ISOSORBIDE-5-MONONITRATE SUSTAINED RELEASE) AND BETA-BLOCKER WITH VASODILATING ACTION (NEBIVOLOL) — IN PATIENTS WITH STABLE ANGINA
title_full_unstemmed A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF ANTIANGINAL DRUGS OF DIFFERENT GROUPS — NITROVASODILATATOR (ISOSORBIDE-5-MONONITRATE SUSTAINED RELEASE) AND BETA-BLOCKER WITH VASODILATING ACTION (NEBIVOLOL) — IN PATIENTS WITH STABLE ANGINA
title_short A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF ANTIANGINAL DRUGS OF DIFFERENT GROUPS — NITROVASODILATATOR (ISOSORBIDE-5-MONONITRATE SUSTAINED RELEASE) AND BETA-BLOCKER WITH VASODILATING ACTION (NEBIVOLOL) — IN PATIENTS WITH STABLE ANGINA
title_sort comparative study of efficacy and tolerability of antianginal drugs of different groups nitrovasodilatator isosorbide 5 mononitrate sustained release and beta blocker with vasodilating action nebivolol in patients with stable angina
topic beta-blocker
isosorbide-5-mononitrate
antianginal efficacy
ischemic heart disease
exercise tolerance test
side effects
url https://www.rpcardio.online/jour/article/view/897
work_keys_str_mv AT syumartsevich acomparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT npkutishenko acomparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT vaegorov acomparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT avzagrebelnyy acomparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT aaserazhim acomparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT yuvlukina acomparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT nadmitrieva acomparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT syumartsevich comparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT npkutishenko comparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT vaegorov comparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT avzagrebelnyy comparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT aaserazhim comparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT yuvlukina comparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina
AT nadmitrieva comparativestudyofefficacyandtolerabilityofantianginaldrugsofdifferentgroupsnitrovasodilatatorisosorbide5mononitratesustainedreleaseandbetablockerwithvasodilatingactionnebivololinpatientswithstableangina